Skip to main content
SpringerLink
Log in

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Imatinib is the treatment of choice for FIP1L1-PDGFRα (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 54:1–27

    Article  PubMed  CAS  Google Scholar 

  2. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutre SE (2004) The FIP1L1-PDGFRa fusion tyrosine kinase in hyper eosinophilic syndrome and chronic eosinophilic leukaemia: implications for diagnosis, classification and management. Blood 103:2879–2891

    Article  PubMed  CAS  Google Scholar 

  3. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103:473–478

    Article  PubMed  CAS  Google Scholar 

  4. Schaller JL, Burkland GA (2001) Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 3:9

    CAS  Google Scholar 

  5. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, De Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92:1173–1179

    Article  PubMed  CAS  Google Scholar 

  6. Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, Reiter A, Hochhaus A, Holowiecki J (2006) The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol 76:535–536

    Article  PubMed  Google Scholar 

  7. Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I, Carturan S, Messa E, Fava M, Giugliano E, Rosso V, Catalano R, Merante S, Nicoli P, Rondomi M, Ottaviani E, Soverini S, Tiribelli M, Pane F, Baccarani M, Saglio G (2007) WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukaemia. Leukemia 21:1442–1450

    Article  PubMed  CAS  Google Scholar 

  8. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22

    Article  PubMed  CAS  Google Scholar 

  9. Cools J, De Angelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRa and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl J Med 348:1201–1214

    Article  PubMed  CAS  Google Scholar 

  10. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyi AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A (2006) FIP1L1-PDGFRa in eosinophilic disorders: prevalence in routine clinical practice, long term experience with imatinib therapy and a critical review of the literature. Leuk Res 30:965–970

    Article  PubMed  CAS  Google Scholar 

  11. Tefferi A, Patnaik MM, Pardanani A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133:468–492

    Article  PubMed  CAS  Google Scholar 

  12. Klion AD, Robyn J, Maric I, Fu W, Schmid I, Lemery S, Noel P, Law MA, Hatsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB (2007) Relapse following discontinuation of imatinib mesylate therapy for FIP1L1-PDGFRa-positive chronic eosinophilic leukaemia: implications for optimal dosing. Blood 110:3352–3356

    Article  Google Scholar 

  13. Helbig G, Holowiecka SB, Majewski M, Calbecka M, Gajkowska G, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Holowiecki J (2008) A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRa-expressing patients. Br J Haematol 141:200–204

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy

    Massimo Breccia, Laura Cannella, Caterina Stefanizzi, Agostino Tafuri, Angelo Fama, Michelina Santopietro & Giuliana Alimena

  2. Department of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Orbassano, Turin, Italy

    Daniela Cilloni & Giuseppe Saglio

  3. Department of Human Biotechnology and Hematology, Via Benevento 6, 00161, Rome, Italy

    Massimo Breccia

Authors
  1. Massimo Breccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Cilloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura Cannella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Caterina Stefanizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Agostino Tafuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angelo Fama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michelina Santopietro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giuseppe Saglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Giuliana Alimena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Breccia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breccia, M., Cilloni, D., Cannella, L. et al. Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. Cancer Chemother Pharmacol 63, 1161–1163 (2009). https://doi.org/10.1007/s00280-008-0858-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0858-8

Keywords

Search

Navigation